

Edgar Filing: RESPIRONICS INC - Form 10-Q

RESPIRONICS INC
Form 10-Q
November 14, 2001

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549

FORM 10-Q

(Mark One)

Quarterly Report pursuant to section 13 or 15(d) of the Securities Exchange

Act of 1934 for the quarterly period ended September 30, 2001 or

Transition Report pursuant to section 13 or 15(d) of the Securities
Exchange Act of 1934 for the transition period from _____ to _____

Commission File No. 000-16723

RESPIRONICS, INC.

(Exact name of registrant as specified in its charter)

Delaware 25-1304989
(State or other jurisdiction of (I.R.S. Employer Identification Number)
incorporation or organization)

1501 Ardmore Blvd.
Pittsburgh, Pennsylvania 15221
(Address of principal executive offices) (Zip Code)

(Registrant's Telephone Number, including area code) 412-731-2100

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes No .

As of October 31, 2001, there were 34,110,511 shares of Common Stock of the
registrant outstanding, of which 3,633,836 were held in treasury.

INDEX

RESPIRONICS, INC.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited).

Independent Accountants' Review Report

Edgar Filing: RESPIRONICS INC - Form 10-Q

Consolidated balance sheets -- September 30, 2001 and June 30, 2001.

Consolidated statements of operations -- Three months ended September 30, 2001 and 2000.

Consolidated statements of cash flows -- Three months ended September 30, 2001 and 2000.

Notes to consolidated financial statements - September 30, 2001.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

Item 2. Changes in Securities.

Item 3. Defaults Upon Senior Securities.

Item 4. Submission of Matters to a Vote of Security Holders.

Item 5. Other Information.

Item 6. Exhibits and Reports on Form 8-K.

SIGNATURES

Independent Accountants' Review Report

Board of Directors
Respironics, Inc. and Subsidiaries

We have reviewed the accompanying condensed consolidated balance sheet of Respironics, Inc. and Subsidiaries as of September 30, 2001, and the related condensed consolidated statements of operations for the three-month periods ended September 30, 2001 and 2000, and the condensed consolidated statements of cash flows for the three-month periods ended September 30, 2001 and 2000. These financial statements are the responsibility of the Company's management.

We conducted our reviews in accordance with standards established by the American Institute of Certified Public Accountants. A review of interim financial information consists principally of applying analytical procedures to financial data, and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with auditing standards generally accepted in the United States, which will be performed for the full year with the objective of expressing an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should

Edgar Filing: RESPIRONICS INC - Form 10-Q

be made to the accompanying condensed consolidated financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States.

We have previously audited, in accordance with auditing standards generally accepted in the United States, the consolidated balance sheet of Respironics, Inc. and Subsidiaries as of June 30, 2001, and the related consolidated statements of operations, shareholders' equity, and cash flows for the year then ended not presented herein and in our report dated July 24, 2001, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of June 30, 2001, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

/s/ Ernst & Young LLP

Pittsburgh, Pennsylvania
October 23, 2001

CONSOLIDATED BALANCE SHEETS (UNAUDITED)

RESPIRONICS, INC. AND SUBSIDIARIES

	September 2001 -----
ASSETS	
CURRENT ASSETS	
Cash and short-term investments	\$ 37,
Trade accounts receivable, less allowance for doubtful accounts of \$17,374,000 and \$16,457,000	96,
Inventories	69,
Prepaid expenses and other	11,
Deferred income tax benefits	14,
TOTAL CURRENT ASSETS	230,
PROPERTY, PLANT AND EQUIPMENT	
Land	2,
Building	8,
Machinery and equipment	87,
Furniture, office and computer equipment	59,
Leasehold improvements	5,
Less allowances for depreciation and amortization	163,
	69,
OTHER ASSETS	13,
GOODWILL	59,

Edgar Filing: RESPIRONICS INC - Form 10-Q

	\$ 372,
	=====
LIABILITIES AND SHAREHOLDERS' EQUITY	
CURRENT LIABILITIES	
Accounts payable	\$ 25,
Accrued expenses and other	20,
Current portion of long-term obligations	

TOTAL CURRENT LIABILITIES	47,
LONG-TERM OBLIGATIONS	
	79,
SHAREHOLDERS' EQUITY	
Common Stock, \$.01 par value; authorized 100,000,000 shares; issued and outstanding 34,089,171 shares at September 30, 2001 and 34,013,785 shares at June 30, 2001	
Additional capital	122,
Accumulated other comprehensive loss	(3,
Retained earnings	168,
Treasury stock	(42,

TOTAL SHAREHOLDERS' EQUITY	245,

	\$ 372,
	=====

See notes to consolidated financial statements.

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

RESPIRONICS, INC. AND SUBSIDIARIES

	Three m
	September 30
	2001

Net sales	\$ 107,408,622
Cost of goods sold	56,508,529

GROSS MARGIN	50,900,093
General and administrative expenses	12,909,013
Sales, marketing and commission expenses	19,498,801
Research and development expenses	4,313,602
Interest expense	1,074,588
Other income	(323,432)

	37,472,572

INCOME BEFORE INCOME TAXES	13,427,521

Edgar Filing: RESPIRONICS INC - Form 10-Q

Income taxes	5,325,355

NET INCOME	\$ 8,102,166
	=====
Basic earnings per share	\$ 0.27
	=====
Basic shares outstanding	30,408,210
Diluted earnings per share	\$ 0.26
	=====
Diluted shares outstanding	31,361,104

See notes to consolidated financial statements.

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

RESPIRONICS, INC. AND SUBSIDIARIES

	Three Months 2001

OPERATING ACTIVITIES	
Net income	\$ 8,102,166
Adjustments to reconcile net income to net cash provided by operating activities:	
Depreciation and amortization	8,527,590
Changes in operating assets and liabilities:	
Decrease in accounts receivable	1,307,520
Decrease (increase) in inventories	4,080,150
Change in other operating assets and liabilities	(2,063,040)

NET CASH PROVIDED BY OPERATING ACTIVITIES	19,954,396
INVESTING ACTIVITIES	
Purchase of property, plant and equipment	(7,104,150)
Additional purchase price for acquired business	(606,510)

NET CASH USED BY INVESTING ACTIVITIES	(7,710,660)
FINANCING ACTIVITIES	
Net decrease in borrowings	(3,203,950)
Issuance of common stock	1,024,790
Use of treasury stock, net	42,000

NET CASH (USED) PROVIDED BY FINANCING ACTIVITIES	(2,137,160)

Edgar Filing: RESPIRONICS INC - Form 10-Q

INCREASE IN CASH AND SHORT-TERM INVESTMENTS	10,106,56
Cash and short-term investments at beginning of period	27,320,91

CASH AND SHORT-TERM INVESTMENTS AT END OF PERIOD	\$ 37,427,47
	=====

See notes to consolidated financial statements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

RESPIRONICS, INC. AND SUBSIDIARIES

September 30, 2001

NOTE A -- BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended September 30, 2001 are not necessarily indicative of the results that may be expected for the year ended June 30, 2002. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended June 30, 2001.

NOTE B -- INVENTORIES

The composition of inventory is as follows:

	September 30 2001	June 30 2001
	-----	-----
Raw materials	\$17,935,000	\$20,738,000
Work-in-process	5,154,000	5,961,000
Finished goods	46,249,000	46,719,000
	-----	-----
	\$69,338,000	\$73,418,000
	=====	=====

NOTE C -- CONTINGENCIES

As previously disclosed, the Company is party to actions filed in a Federal District Court in January 1995 and June 1996 in which a competitor alleges that

Edgar Filing: RESPIRONICS INC - Form 10-Q

the Company's manufacture and sale in the United States of certain products infringes four of the competitor's patents. In its response to these actions, the Company has denied the allegations and has separately sought judgment that the claims under the patents are invalid or unenforceable and that the Company does not infringe upon the

patents. The January 1995 and June 1996 actions have been consolidated, and discovery is ongoing. The Court has granted the Company's various motions for summary judgment and held that the Company does not infringe any of the competitor's four patents at issue. The competitor may seek an appeal of those decisions. In any event, the Company intends to continue to pursue its claims that the competitor's patents are invalid or unenforceable.

The Company is, as a normal part of its business operations, a party to other legal proceedings in addition to those previously described by filings of the Company. Legal counsel has been retained for each proceeding and none of these proceedings is expected to have a material adverse impact on the Company's results of operations or financial condition.

NOTE D -- RESTRUCTURING CHARGES

In July 1999, the Company announced a major restructuring of its U.S. operations that included facility closings and downsizings, a divisional and management realignment, and an approximate ten percent workforce reduction associated with those changes. The following table summarizes these restructuring charges and corresponding expenditures.

RECONCILIATION OF RESTRUCTURING RESERVES

	Employee Severance Costs	Asset Write-Downs	Lease & Other Expe
	-----	-----	-----
Balance at July 1, 1999	\$ -	\$ -	\$ -
Restructuring charges (net)	6,300,000	8,900,000	
Cash expenditures	(3,100,000)	-	
Noncash expenditures	-	(1,700,000)	
	-----	-----	-----
Balance at June 30, 2000	3,200,000	7,200,000	
	-----	-----	-----
Restructuring charges (net)	(200,000)	1,000,000	
Cash expenditures	(1,500,000)	-	
Noncash expenditures	-	(2,500,000)	
	-----	-----	-----
Balance at June 30, 2001	1,500,000	5,700,000	
	-----	-----	-----
Restructuring charges (net)	-	-	
Cash expenditures	(400,000)	-	
Noncash expenditures	-	(400,000)	
	-----	-----	-----
Balance at September 30, 2001	\$ 1,100,000	\$ 5,300,000	\$ -
	=====	=====	=====

Edgar Filing: RESPIRONICS INC - Form 10-Q

Restructuring costs incurred but not yet paid have been credited to accrued expense and asset write-downs have been credited against the applicable asset accounts. Substantially all of the remaining restructuring accruals as of September 30, 2001 are expected to be paid out during fiscal year 2002.

NOTE E - COMPREHENSIVE INCOME (LOSS)

The components of comprehensive income (loss), net of tax, were as follows:

	Three Months Ended September 30, 2001	September 30, 2000
	-----	-----
Net income	\$ 8,102,000	\$ 6,291,0
Foreign currency translation gains (losses)	735,000	(976,0
	-----	-----
Comprehensive income	\$ 8,837,000	\$ 5,315,0
	=====	=====

NOTE F - RECENT ACCOUNTING PRONOUNCEMENTS

In June 2001, the Financial Accounting Standards Board issued Statements of Financial Accounting Standards No. 141, "Business Combinations," and No. 142, "Goodwill and Other Intangible Assets," effective for fiscal years beginning after December 15, 2001. Under the new rules, goodwill and intangible assets deemed to have indefinite lives will no longer be amortized but will be subject to annual impairment tests in accordance with the Statements. Other intangible assets will continue to be amortized over their useful lives.

The Company will apply the new rules on accounting for goodwill and other intangible assets beginning in the first quarter of fiscal year 2003. Application of the nonamortization provisions of the Statement is expected to result in an increase in annual net income, the impact of which is not yet fully determined. During fiscal year 2003, the Company will perform the first of the required impairment tests of goodwill and indefinite lived intangible assets as of July 1, 2002.

CAUTIONARY STATEMENT FOR PURPOSES OF THE "SAFE HARBOR" PROVISIONS OF THE PRIVATE SECURITIES REFORM ACT OF 1995.

The statements contained in this Quarterly Report on Form 10-Q, specifically those contained in Item 2 "Management's Discussion and Analysis of Financial Condition and Results of Operations", along with statements in other reports filed with the Securities and Exchange Commission, external documents and oral presentations which are not historical are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21B of the Securities and Exchange Act of 1934, as amended. These forward-looking statements represent the Company's present expectations or beliefs concerning future events. The Company cautions that such statements are qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Results actually

Edgar Filing: RESPIRONICS INC - Form 10-Q

achieved may differ materially from expected results included in these statements. Those factors include, but are not limited to, the following: foreign currency fluctuations, regulations and other factors affecting operations and sales outside the United States including potential future effects of the change in sovereignty of Hong Kong, customer consolidation and concentration, increasing price competition and other competitive factors in the sale of products, the success of programs, interest rate fluctuations, intellectual property and related litigation, other litigation, FDA and other government regulation, and third party reimbursement.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

RESULTS OF OPERATIONS

Net sales for the three months ended September 30, 2001 were \$107,409,000 representing a 17% increase over the sales of \$92,064,000 recorded for the three months ended September 30, 2000. Increases in unit and dollar sales for the Company's sleep apnea therapy devices (the Company's largest product line) and oxygen concentrator devices, as well as increases in the sales of masks and accessories, helped to drive the increase in sales for the quarter. Sales of the Company's non-invasive ventilation devices also increased during the quarter, particularly sales of the Company's BiPAP(R) Synchrony(TM) Ventilatory Support System, which was introduced during fiscal year 2001. These product lines comprise the major part of the Company's homecare product offerings. Sales of the Company's asthma and allergy products and its domestic hospital products also increased during the current quarter.

The Company's gross profit was 47% of net sales for the quarters ended September 30, 2001 and 2000. This static gross profit percentage reflects the impact of higher revenue levels, offset by sales mix and selling price decreases consistent with those seen in prior years.

General and administrative expenses were \$12,909,000 (12% of net sales) for the quarter ended September 30, 2001 as compared to \$10,870,000 (12% of net sales) for the quarter ended September 30, 2000. The increase in absolute dollars of general and administrative expenses for the current quarter was due primarily to increases in spending consistent with the growth of the Company's business, including credit and collection department expenses.

Sales, marketing and commission expenses were \$19,499,000 (18% of net sales) for the quarter ended September 30, 2001 as compared to \$16,823,000 (18% of net sales) for the quarter ended September 30, 2000. The increase in absolute dollars of expense for the current quarter was due primarily to increased sales (resulting in higher commission and bonus expenses) and increased sales, marketing, product support, and service activity levels in the Company's homecare and hospital product lines during the current year.

Research and development expenses were \$4,314,000 (4% of net sales) for the quarter ended September 30, 2001 as compared to \$3,371,000 (4% of net sales) for the quarter ended September 30, 2000. The increase in absolute dollars of expense for the current quarter was due primarily to the timing of research and development projects. Significant product development efforts are ongoing and new product launches in many of the Company's major product lines are scheduled for the remainder of fiscal year 2002. Additional development work and clinical trials are being conducted in certain

product areas outside the Company's current core products, including congestive heart failure.

Edgar Filing: RESPIRONICS INC - Form 10-Q

The Company's effective income tax rate was approximately 40% for the quarters ended September 30, 2001 and 2000.

As a result of the factors described above, the Company's net income was \$8,102,000 (8% of net sales) or \$0.26 per diluted share for the quarter ended September 30, 2001 as compared to net income of \$6,291,000 (7% of net sales) or \$0.21 per diluted share for the quarter ended September 30, 2000.

FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

The Company had working capital of \$182,648,000 at September 30, 2001 and \$171,985,000 at June 30, 2001. Net cash provided by operating activities was \$19,954,000 for the three months ended September 30, 2001 as compared to \$8,902,000 for the three months ended September 30, 2000. The increase in cash provided by operating activities for the current three-month period was primarily due to higher earnings and reductions in inventory as compared to an inventory increase in the prior year.

Net cash used by investing activities was \$7,711,000 for the three months ended September 30, 2001 as compared to \$9,092,000 for the three months ended September 30, 2000. Cash used by investing activities for both periods include capital expenditures, including the purchase of leasehold improvements, production equipment, computer hardware and software, and telecommunications and office equipment. In addition, cash used by investing activities in the periods described includes additional purchase price paid for a previously acquired business pursuant to the terms of that acquisition agreement. The funding for investment activities in both periods was provided by positive cash flow from operating activities and accumulated cash and short-term investments.

Net cash used or provided by financing activities includes repayments under the Company's various long-term obligations and proceeds from the issuance of common stock under the Company's stock option plans. Net cash used by financing activities was \$2,137,000 for the three months ended September 30, 2001 as compared to net cash provided by financing activities of \$265,000 for the three months ended September 30, 2000. The increase in cash used by financing activities was due primarily to a repayment of \$3,000,000 on the Company's revolving credit facility during the current quarter.

The Company believes that projected positive cash flow from operating activities, the availability of additional funds under its revolving credit facility (totaling approximately \$44,900,000 at September 30, 2001), and its accumulated cash and short-term investments will be sufficient to meet its current and presently anticipated future needs for the next twelve months for operating

activities (including payments against restructuring accruals), investing activities, and financing activities (primarily consisting of scheduled payments on long-term debt).

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

The Company is exposed to market risk from changes in interest rates and foreign exchange rates.

Interest Rates: The Company's primary interest rate risk relates to its long-term debt obligations. At September 30, 2001, the Company had total long-term debt obligations, including the current portion of those obligations, of \$80,850,000. Of that amount, \$1,950,000 was in fixed rate obligations and \$78,900,000 was in variable rate obligations. Assuming a 10% increase in

Edgar Filing: RESPIRONICS INC - Form 10-Q

interest rates on the Company's variable rate obligations (i.e. an increase from the September 30, 2001 weighted average interest rate of 3.72% to a weighted average interest rate of 4.09%), annual interest expense would be approximately \$294,000 higher based on the September 30, 2001 outstanding balance of variable rate obligations. The Company has no interest rate swap or exchange agreements.

Foreign Exchange Rates: Information relating to the sensitivity to foreign currency exchange rate changes is omitted because foreign exchange exposure risk has not materially changed from that disclosed in the Company's Annual Report on Form 10-K for the year ended June 30, 2001.

Inflation

Inflation has not had a significant effect on the Company's business during the periods discussed.

Recent Accounting Pronouncements

In June 2001, the Financial Accounting Standards Board issued Statements of Financial Accounting Standards No. 141, "Business Combinations," and No. 142, "Goodwill and Other Intangible Assets," effective for fiscal years beginning after December 15, 2001. Under the new rules, goodwill and intangible assets deemed to have indefinite lives will no longer be amortized but will be subject to annual impairment tests in accordance with the Statements. Other intangible assets will continue to be amortized over their useful lives.

The Company will apply the new rules on accounting for goodwill and other intangible assets beginning in the first quarter of fiscal year 2003. Application of the nonamortization provisions of the Statement is expected to result in an increase in annual net income, the impact of which is not yet fully determined. During fiscal year 2003, the Company will perform the first of the required impairment tests of goodwill and indefinite lived intangible assets as of July 1, 2002.

In August 2001, Statement of Financial Accounting Standards No. 143 ("FAS 143"), "Accounting for Asset Retirement Obligations," was issued. This Statement requires recording the fair value of a liability for an asset retirement obligation in the period in which it is incurred, and a corresponding increase in the carrying value of the related long-lived asset. Over time, the liability is accreted to its present value each period, and the capitalized cost is depreciated over the useful life of the related asset. Upon settlement of the liability, it is either settled for its recorded amount or a gain or loss upon settlement is recorded. FAS 143 is effective for the Company's fiscal year ended June 30, 2003. The Company is currently assessing, but has not yet determined, the impact of FAS 143 on its financial position and results of operations.

In August 2001, Statement of Financial Accounting Standards No. 144 ("FAS 144"), "Accounting for the Impairment or Disposal of Long-Lived Assets," was issued. This Statement addresses financial accounting and reporting for the impairment or disposal of long-lived assets. This Statement supercedes FAS Statement No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of," and the accounting and reporting provisions of Accounting Principles Board ("APB") Opinion No. 30, "Reporting the Results of Operations - Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions," for the disposal of a segment of a business (as previously defined in that Opinion). FAS 144 is effective for the Company's fiscal year ended June 30, 2003. The Company is currently assessing, but has not yet determined, the impact of FAS 144 on its financial position and results of

Edgar Filing: RESPIRONICS INC - Form 10-Q

operations.

PART 2 OTHER INFORMATION

Item 1: Legal Proceedings

The Company is, as a normal part of its business operations, a party to other legal proceedings in addition to those previously described by filings of the Company. Legal counsel has been retained for each proceeding and none of these proceedings is expected to have a material adverse impact on the Company's results of operations or financial condition.

Item 2: Changes in Securities

- (a) Not applicable
- (b) Not applicable
- (c) Not applicable

Item 3: Defaults Upon Senior Securities

- (a) Not applicable
- (b) Not applicable

Item 4: Submission of Matters to a Vote of Security Holders

Not applicable.

Item 5: Other Information

Not applicable

Item 6: Exhibits and Reports on Form 8-K

- (a) Exhibits
Exhibit 15 Acknowledgement of Ernst & Young LLP.
- (b) Reports on Form 8-K
Not applicable

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Edgar Filing: RESPIRONICS INC - Form 10-Q

RESPIRONICS, INC.

Date: November 14, 2001

/s/ Daniel J. Bevevino

Daniel J. Bevevino
Vice President, and Chief
Financial and Principal
Accounting Officer

Signing on behalf of the
registrant and as Chief
Financial and Principal
Accounting Officer